Searched over 200M research papers
10 papers analyzed
Some studies suggest that in vitro maturation (IVM) may be a safer and more effective alternative to conventional IVF for women with polycystic ovarian syndrome, while other studies indicate that IVM is less successful with lower pregnancy and live birth rates.
20 papers analyzed
Polycystic ovarian syndrome (PCOS) is a common endocrine disorder affecting 4% to 7% of women of reproductive age and is a leading cause of subfertility, affecting up to 50% of women seeking fertility treatments. In vitro fertilization (IVF) is a widely used assisted reproductive technology (ART) for women with PCOS, but it presents unique challenges and considerations.
Women with PCOS undergoing IVF often experience an exaggerated ovarian response to stimulation, leading to the retrieval of a large number of oocytes, many of which may be immature or of uneven quality . Despite this, studies have shown that the number of oocytes retrieved per cycle is generally higher in PCOS patients compared to non-PCOS controls . However, the fertilization rates in PCOS patients tend to be lower, which can impact overall pregnancy outcomes .
Clinical pregnancy rates per cycle in women with PCOS undergoing conventional IVF are comparable to those in women without PCOS . However, a meta-analysis indicated that while PCOS patients have similar clinical pregnancy rates, they also face higher risks of miscarriage and other pregnancy-related complications. Despite these challenges, the live birth rates per cycle are generally similar between PCOS and non-PCOS patients .
In vitro maturation (IVM) is an emerging alternative to conventional IVF for women with PCOS. IVM involves the retrieval of immature oocytes, which are then matured in the laboratory before fertilization. This approach can reduce the risk of ovarian hyperstimulation syndrome (OHSS), a serious complication associated with conventional IVF . Studies have shown that IVM can result in higher clinical pregnancy rates compared to conventional IVF, although the evidence is still of very low quality.
While IVM shows promise, it has been associated with lower live birth rates in fresh cycles compared to standard IVF. However, when considering frozen embryo transfer (FET) cycles, the live birth rates between IVM and IVF are comparable. This suggests that while IVM may be less effective in fresh cycles, it can still be a viable option when combined with FET.
Recent studies have highlighted the potential benefits of frozen embryo transfer (FET) over fresh embryo transfer in women with PCOS. FET has been associated with higher live birth rates and lower risks of OHSS and pregnancy loss compared to fresh embryo transfer. However, FET may also carry a higher risk of preeclampsia.
The choice between fresh and frozen embryo transfer should be carefully considered, taking into account the individual patient's risk factors and overall health. For women with PCOS, FET may offer a safer and more effective option, particularly in reducing the risk of OHSS.
IVF remains a critical option for women with PCOS seeking to conceive, but it comes with unique challenges such as higher risks of OHSS and variable oocyte quality. IVM presents a promising alternative, particularly in reducing OHSS risk, though it may result in lower live birth rates in fresh cycles. The use of frozen embryo transfer can further optimize outcomes by increasing live birth rates and reducing complications. Ongoing research and well-conducted randomized controlled trials are essential to refine these approaches and improve outcomes for women with PCOS undergoing IVF.
Most relevant research papers on this topic